Acute heart failure in surgery of coronary artery disease

[1]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[2]  O. Stukalova,et al.  [The possibilities of using levosimendan in medical preparation to Coronary Artery Bypass Grafting in coronary artery disease patients with low left ventricular ejection fraction]. , 2020, Terapevticheskii arkhiv.

[3]  В. В. Ломиворотов,et al.  Синдром низкого сердечного выброса в кардиохирургии , 2019 .

[4]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[5]  C. Torp‐Pedersen,et al.  Intraoperative milrinone versus dobutamine in cardiac surgery patients: a retrospective cohort study on mortality , 2018, Critical Care.

[6]  K. Anstrom,et al.  Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial , 2017, JAMA.

[7]  M. Munger,et al.  Effect of Inpatient Dobutamine versus Milrinone on Out‐of‐Hospital Mortality in Patients with Acute Decompensated Heart Failure , 2017, Pharmacotherapy.

[8]  K. Sliwa,et al.  Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance , 2016, Intensive Care Medicine.

[9]  И. А. Козлов,et al.  Десять лет чреспищеводной эхокардиографии в отечественной кардиоанестезиологии , 2015 .

[10]  R. Mehta,et al.  Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. , 2015, International journal of cardiology.

[11]  Q. Ji,et al.  Predictors of low cardiac output syndrome after isolated coronary artery bypass grafting. , 2015, International heart journal.

[12]  A. Parkhomenko,et al.  Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. , 2014, International journal of cardiology.

[13]  I. Kozlova,et al.  Natriuretic Peptides: Biochemistry, Physiology, Clinical Implication , 2014 .

[14]  R. Dennis,et al.  Hemoglobin and B-type natriuretic peptide preoperative values but not inflammatory markers, are associated with postoperative morbidity in cardiac surgery: a prospective cohort analytic study , 2013, Journal of Cardiothoracic Surgery.

[15]  C. Chin,et al.  Plasma B‐type natriuretic peptide in predicting outcomes of elective coronary artery bypass surgery , 2013, The Kaohsiung journal of medical sciences.

[16]  D. A. Nikolaev,et al.  Evaluation of nutritional screening tools for patients scheduled for cardiac surgery. , 2013, Nutrition.

[17]  A. Parkhomenko,et al.  Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. , 2012, International journal of cardiology.

[18]  Mario J. Garcia,et al.  CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysis of prospective trials. , 2012, JACC. Cardiovascular imaging.

[19]  M. Sá,et al.  Risk factors for low cardiac output syndrome after coronary artery bypass grafting surgery. , 2012, Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade Brasileira de Cirurgia Cardiovascular.

[20]  A. Cheung,et al.  Preoperative total lymphocyte count in peripheral blood as a predictor of poor outcome in adult cardiac surgery. , 2011, Journal of cardiothoracic and vascular anesthesia.

[21]  M. Maganti,et al.  Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: trends over 20 years. , 2011, The Annals of thoracic surgery.

[22]  Л. А. Кричевский,et al.  Применение левосимендана в кардиоанестезиологии , 2011 .

[23]  R. Porcher,et al.  Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods , 2011, Intensive Care Medicine.

[24]  E. Schmid,et al.  Introduction and epidemiology , 2018, ESC CardioMed.

[25]  Ю. В. Никифоров,et al.  Значение сердечного пептида NT-proBNP в оценке риска реваскуляризации миокарда у больных со сниженной фракцией изгнания левого желудочка , 2010 .

[26]  M. Elayda,et al.  Obesity is associated with increased morbidity after coronary artery bypass graft surgery in patients with renal insufficiency. , 2009, The Journal of thoracic and cardiovascular surgery.

[27]  D. DeMets,et al.  Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials , 2009, European heart journal.

[28]  G. Hillis,et al.  N-terminal pro-B-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study. , 2009, British journal of anaesthesia.

[29]  G. Klemenzson,et al.  Brain natriuretic peptide is a good predictor for outcome in cardiac surgery , 2008, Acta anaesthesiologica Scandinavica.

[30]  И. А. Козлов,et al.  Прогнозирование сроков нормализации сердечной функции после операций с искусственным кровообращением , 2007 .

[31]  D. Farmakis,et al.  Classical inotropes and new cardiac enhancers , 2007, Heart Failure Reviews.

[32]  W. Vaughn,et al.  Obesity in Diabetic Patients Undergoing Coronary Artery Bypass Graft Surgery Is Associated with Increased Postoperative Morbidity , 2006, Anesthesiology.

[33]  M. Gheorghiade,et al.  Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. , 2005, The American journal of cardiology.

[34]  Jeroen J. Bax,et al.  Evaluation of hibernating myocardium , 2004, Heart.

[35]  R. Kazanegra,et al.  Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. , 2004, Journal of the American College of Cardiology.

[36]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[37]  L. Shaw,et al.  Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. , 2002, Journal of the American College of Cardiology.

[38]  M. Charlson,et al.  Predictors and outcomes of cardiac complications following elective coronary bypass grafting. , 1999, Proceedings of the Association of American Physicians.

[39]  R. Califf,et al.  Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.

[40]  M. Nieminen,et al.  Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. , 1998, European heart journal.

[41]  R. Raper,et al.  Epinephrine-induced lactic acidosis following cardiopulmonary bypass. , 1997, Critical care medicine.

[42]  T. David,et al.  Predictors of low cardiac output syndrome after coronary artery bypass. , 1996, The Journal of thoracic and cardiovascular surgery.

[43]  J. Elefteriades,et al.  Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. , 1993, Journal of the American College of Cardiology.

[44]  M. Nishimura,et al.  Effects of norepinephrine on renal function in septic patients with normal and elevated serum lactate levels. , 1989, Critical care medicine.

[45]  R. Tuttle,et al.  Dobutamine: DEVELOPMENT OF A NEW CATECHOLAMINE TO SELECTIVELY INCREASE CARDIAC CONTRACTILITY , 1975, Circulation research.